GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lonafarnib overview

Lonafarnib (Zokinvy) is a synthetic tricyclic derivative of carboxamide with antineoplastic properties. It is formulated as hard gelatin capsules for oral route of administration. Zokinvy is indicated in patients 12 months of age and older with a body surface area of 0.39 m2 and above to reduce risk of mortality in Hutchinson-Gilford Progeria Syndrome and for treatment of processing-deficient Progeroid Laminopathies with either Heterozygous LMNA mutation with progerin-like protein accumulation or Homozygous or compound heterozygous ZMPSTE24 mutations.

Lonafarnib (Sarasar, SCH 66336) is under development for the treatment of Hepatitis D, brain tumors such as glioblastoma multiforme and gliosarcoma. It is a synthetic tricyclic derivative of carboxamide. Lonarfanib binds to and inhibits farnesyl transferase. It was also under development for the treatment of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, non-small cell lung cancer, squamous cell carcinoma of the head and neck, myelodysplastic syndrome and chronic myelomonocytic leukemia (CMML), adenocarcinoma of prostate cancer and metastatic breast cancer.

Eiger BioPharmaceuticals overview

Eiger BioPharmaceuticals (Eiger), formerly known as Celladon, is a biopharmaceutical company that focuses on the clinical-stage development and commercialization of novel drugs for the treatment of orphan diseases. The company provides products such as Lonafarnib, Peginterferon lambda, avexitide, lonafarnib and ritonavir for hepatitis delta virus (HDV) infection, peginterferon lambda for hepatitis delta virus (HDV) infection, avexitide for post bariatric hypoglycemia (PBH), avexitide for congenital hyperinsulinism (HI) among others. The company also offers post-bariatric hypoglycemia prevention services. It also offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. Eiger is headquartered in Palo Alto, California, the US.

For a complete picture of Lonafarnib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Smarter leaders trust GlobalData